FGFR1 and diabetes mellitus: After adjustment for sex, pathologic stage, diabetes, adjuvant chemotherapy and other factors, FGFR1 amplification remained associated with significantly shorter OS (adjusted hazard ratio [AHR], 1.61; 95% CI, 1.10-2.43, P=0.004) (Table 2).